Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma

Journal of Clinical Oncology

Volumn 22, Issue 6, 2004, Pages 984-993

  Gajjar, Amar ^a   Hernan, Roberto ^a   Kocak, Mehmet ^a   Fuller, Christine ^a   Lee, Youngsoo ^a   McKinnon, Peter J ^a   Wallace, Dana ^a   Lau, Ching ^a   Chintagumpala, Murali ^a   Ashley, David M ^a   Kellie, Stewart J ^a   Kun, Larry ^a   Gilbertson, Richard J ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MOLECULAR MARKER; NEUROTROPHIN 3 RECEPTOR; TUMOR MARKER;

ARTICLE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MEDULLOBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; WESTERN BLOTTING; ADOLESCENT; AUSTRALIA; CEREBELLUM TUMOR; CHILD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EVALUATION; FEASIBILITY STUDY; FEMALE; GENETICS; INFANT; LABORATORY DIAGNOSIS; MALE; MULTICENTER STUDY; ORGANIZATION AND MANAGEMENT; PATHOLOGY; PREDICTION AND FORECASTING; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; UNITED STATES;

ADOLESCENT; AUSTRALIA; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; PATHOLOGY, CLINICAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RISK ASSESSMENT; RISK FACTORS; SPECIMEN HANDLING; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 1842614251     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.032     Document Type: Article

References (47)

1. Zeltzer PM, Boyett JM, Finlay JL, et al: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17:832-845, 1999
2. Ris MD, Packer R, Goldwein J, et al: Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: A Children's Cancer Group study. J Clin Oncol 19:3470-3476, 2001
3. Schwartz CL: Long-term survivors of childhood cancer: The late effects of therapy. Oncologist 4:45-54, 1999
4. Grill J, Renaux VK, Bulteau C, et al: Longterm intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. Int J Radiat Oncol Biol Phys 45: 137-145, 1999
5. Packer RJ: Childhood medulloblastoma: Progress and future challenges. Brain Dev 21:75-81, 1999
6. Kortmann RD, Kuhl J, Timmermann B, et al: Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46:269-279, 2000
7. Taylor RE, Bailey CC, Robinson K, et al: Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 21:1581-1591, 2003
8. Ellison DW, Clifford SC, Gajjar A, et al: What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 7:53-66, 2003
9. Rubnitz JE, Pui CH: Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. Cancer Treat Rev 29:31-44, 2003
10. Brodeur GM: Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 3:203-216, 2003
11. Ellison D: Classifying the medulloblastoma: Insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 28:257-282, 2002
12. Gilbertson R: Paediatric embryonic brain tumours: Biological and clinical relevance of molecular genetic abnormalities. Eur J Cancer 38: 675-685, 2002
13. Strother D, Ashley D, Kellie SJ, et al: Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: Results of a collaborative study. J Clin Oncol 19:2696-2704, 2001
14. Gilbertson RJ, Perry RH, Kelly PJ, et al: Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57:3272-3280, 1997
15. Hernan R, Fasheh R, Calabrese C, et al: ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 63:140-148, 2003
16. Kleihues P, Louis DN, Scheithauer BW, et al: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225, 2002
17. Gilbertson RJ, Bentley L, Hernan R, et al: ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 8:3054-3064, 2002
18. Gilbertson R, Hernan R. Pietsch T, et al: Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma. Genes Chromosomes Cancer 31:288-294, 2001
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. Peto R, Peto J: Asymptotically efficient rank invariant procedures (with discussion). J R Stat Soc A 185-206, 1972
21. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1958
22. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-229, 1972
23. Eberhart CG, Kepner JL, Goldthwaite PT, et al: Histopathologic grading of medulloblastomas: A Pediatric Oncology Group study. Cancer 94:552-560, 2002
24. Bargmann CI, Weinberg RA: Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci U S A 85:5394-5398, 1988
25. Di Marco E, Pierce JH, Knicley CL, et al: Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene. Mol Cell Biol 10:3247-3252, 1990
26. Di Fiore PP, Pierce JH, Kraus MH, et al: ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182, 1987
27. Zhang K, Sun J, Liu N, et al: Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem 271:3884-3890, 1996
28. Muller WJ, Sinn E, Pattengale PK, et al: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115, 1988
29. Guy CT, Webster MA, Schaller M, et al: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89:10578-10582, 1992
30. Yarden Y, Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127-137, 2001
31. Gilbertson RJ, Jaros EB, Perry RH, et al: Prognostic factors in medulloblastoma. Lancet 340:480, 1992
32. Gilbertson R, Wickramasinghe C, Hernan R, et al: Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85:705-712, 2001
33. Pelengaris S, Khan M, Evan G: C-MYC: More than just a matter of life and death. Nat Rev Cancer 2:764-776, 2002
34. Brown HG, Kepner JL, Perlman EJ, et al: "Large cell/anaplastic" medulloblastomas: A Pediatric Oncology Group Study. J Neuropathol Exp Neurol 59:857-865, 2000
35. Eberhart CG, Kratz JE, Schuster A, et al: Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 12:36-44, 2002
36. Herms J, Neidt I, Luscher B, et al: C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 89:395-402, 2000
37. Grotzer MA, Hogarty MD, Janss AJ, et al: MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 7:2425-2433, 2001
38. Bibel M, Barde YA: Neurotrophins: Key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev 14:2919-2937, 2000
39. Kim JY, Sutton ME, Lu DJ, et al: Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 59:711-719, 1999
40. Grotzer MA, Janss AJ, Fung K, et al: TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 18:1027-1035, 2000
41. Palmer SL, Reddick WE, Glass JO, et al: Decline in corpus callosum volume among pediatric patients with medulloblastoma: Longitudinal MR imaging study. AJNR Am J Neuroradiol 23:1088-1094, 2002
42. Palmer SL, Goloubeva O, Reddick WE, et al: Patterns of intellectual development among survivors of pediatric medulloblastoma: A longitudinal analysis. J Clin Oncol 19:2302-2308, 2001
43. Mulhern RK, Palmer SL, Reddick WE. et al: Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol 19:472-479, 2001
44. Heikens J, Michiels EM, Behrendt H, et al: Long-term neuro-endocrine sequelae after treatment for childhood medulloblastoma. Eur J Cancer 34:1592-1597, 1998
45. Silber JH, Radcliffe J, Peckham V, et al: Whole-brain irradiation and decline in intelligence: The influence of dose and age on IQ score. J Clin Oncol 10:1390-1396, 1992
46. Walter AW, Mulhern RK, Gajjar A, et al: Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J Clin Oncol 17: 3720-3728, 1999
47. Packer RJ, Goldwein J, Nicholson HS, et al: Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 17: 2127-2136, 1999